A leading finance and insurance group from China has visited Min-Sheng Hospital, Yi-Der Long Term Care Center, and other health facilities. China Ping An Trust & Investment Co. in Shenzhen was on a fact-finding visit of Taiwan health care institutions. The delegation was very interested in topics ranging from JCI accreditation to executive health checks and long-term care.
A leading finance and insurance group from China has visited Min-Sheng Hospital, Yi-Der Long Term Care Center, and other health facilities. China Ping An Trust & Investment Co. in Shenzhen was on a fact-finding visit of Taiwan health care institutions. The delegation was very interested in topics ranging from JCI accreditation to executive health checks and long-term care.
China Ping An is to invest heavily in health care and long term care facilities in China, and are currently looking to gather expertise and partnerships in Taiwan, Hong Kong and Singapore.
NeoStem is an American innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications that is expanding into research, medical tourism, and China for the commercialization of regenerative medicine and other stem cell applications.
NeoStem (China) has strong support from the Chinese government for commercialization of cosmetic / regenerative medicine applications which will also expedite the process of US development as the company becomes a vertically integrated stem cell operation in a permissive regulatory environment that includes strong government support.
NeoStem has embarked upon several stem cell initiatives in China, including the creation of a separate stem cell operation in China, the construction of a stem cell research facility in Beijing, the establishment of relationships with hospitals to provide stem cell therapies, and the licensing of stem cell therapeutics focused on regenerative medicine applications. During 2010, NeoStem plans to begin offering stem cell banking services and therapies in China, in addition to medical tourism initiatives that will offer these services to those living in developed countries such as the US where such treatments are either unavailable or unaffordable.
NeoStem is targeting the introduction of highly mature U.S.based therapies that lack FDA approval that is necessary for widespread use in the domestic market. NBS China intends to commercialize its first stem cell therapy for orthopedic indications in 2009 while developing a pipeline of additional therapies for central nervous system disease, wound healing, and heart disease. The initial orthopedic market will target 80-100 million arthritis sufferers in China.
NeoStem will also offer medical tourism service centres to serve patients from affluent countries that have more restrictive regulatory processes such as US and Europe. The Company’s medical tourism initiatives in China will offer world-class standard operating procedures, standards of care, and facilities. An estimated 7000 patients have been treated in China’s medical tourism industry since 2001, but the company says that current offerings do not include the world-class standard of care that NeoStem can offer.
©2024 All rights reserved LaingBuisson 
